Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound sirolimus plus long-acting octreotide in metastatic gastroenteropancreatic neuroendocrine tumors
CTR20253602Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus, octreotide in Gastroenteropancreatic Carcinoid Tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Sep 2025; status: active.
02
Drugs
sirolimusoctreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20253602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253602.